NEW YORK (GenomeWeb) – Wells Fargo Securities today upgraded shares of Bruker to an Outperform rating and increased the price range on its stock after a Bruker official said the company plans to further restructure its Chemical and Applied Markets division and grow its presence in the clinical market.

Analyst Tim Evans upgraded Bruker from a previous Market Perform rating and raised the price range on Bruker's shares to between $25 and $27 from an earlier range of $21 to $22.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.